The low prevalence of hypokalaemia found in our patients is of interest. Low-dose thiazides (principally as bendrofluazide, 2.5 mg) are used as first-line treatment for diabetic hypertension in this patient group.
Our data confirm that this rarely produces hypokalaemia.
The high prevalence ofhyperkalaemia found in this study has practical importance, because of the increasing use of ACE inhibitors to treat diabetic patients with hypertension, nephropathy, and the use of these agents or potassium-sparing diuretics in cardiac failure. Some patients may have unsuspected severe hyperkalaemia before commencing these drugs. It is thus particularly important to check potassium levels when starting diabetic patients on these agents, to reduce the small but real risk of producing dangerous hyperkalaemia.
